Skip to content
Open access

Integrated clinical and genetic phenotyping in newly diagnosed pulmonary hypertension: comparative insights across IPAH, CTD-APAH, and CTEPH

Oct 2026 · European Heart Journal · 0 citations

TL;DR

IPH demonstrated the most severe hemodynamic impairment, CTEPH showed intermediate severity, and CTD-APAH exhibited milder pulmonary pressures but more substantial functional limitation, while CTEPH showed intermediate hemodynamic impairment, while CTD-APAH displayed comparatively milder pulmonary pressures but a predominance of WHO functional class III symptoms.

Abstract

The ESC/ERS classification of pul­monary hypertension (PH) is based on distinct clinical phenotypes, which however often overlap significantly in clinical practice. While registries like COMPERA and ASPIRE provide robust hemodynamic comparisons, there remains a paucity of data integrating deep genetic and clinical phenotyping across the spectrum of incident PH in a prospective cohort of consecutive patients. The prospective SPH-RESP study aims to provide a comparison of phenotypic and genotypic characteristics of consecutive, newly diagnosed cases with idiopathic pulmonary arterial hypertension (IPAH), connective tissue disease–associated PAH (CTD-APAH), and chronic thromboembolic PH (CTEPH). Consecutive, newly diagnosed patients with IPAH, CTD-APAH, and CTEPH referred for right heart catheterization at a single PAH center between October 1, 2021, and November 15, 2025 were included. Clinical, laboratory, echocardiographic, and hemodynamic data were analyzed across groups. Within each group, 10 patients underwent PAH gene-panel testing; selection was random in the IPAH group, whereas CTD-APAH and CTEPH patients were chosen to achieve age matching with the IPAH cohort. None had a known family history of PAH. IPAH patients were younger than CTD-APAH and CTEPH patients, and exhibited the most severe pulmonary vascular disease, with higher mean pulmonary artery pressure and pulmonary vascular resistance, and lower cardiac index. Right atrial area was also larger in IPAH, indicating more advanced right-sided remodeling. CTEPH showed intermediate hemodynamic impairment, while CTD-APAH displayed comparatively milder pulmonary pressures but a predominance of WHO functional class III symptoms. Comorbidity burden differed modestly, with diabetes being more frequent in IPAH, see Table 1. Across all etiologies, genetically tested patients were younger, had fewer comorbidities, and better renal function than non-tested patients. The PAH gene-panel did not identify any known pathogenic or likely pathogenic variants. One IPAH patient carried a heterozygous ATP13A3 splice-region variant of uncertain significance (c.3313+4A>G), absent from population databases and predicted to affect RNA splicing. Although ATP13A3 loss-of-function variants are enriched in PAH cohorts, heterozygous variants typically demonstrate incomplete penetrance; therefore, the clinical significance of this finding remains uncertain. IPAH demonstrated the most severe hemodynamic impairment, CTEPH showed intermediate severity, and CTD-APAH exhibited milder pulmonary pressures but more substantial functional limitation. The absence of known PAH-pathogenic genetic variants in this cohort underscores the limited diagnostic yield of broad gene-panel testing in routine clinical populations and the need for larger studies to clarify the genetic contribution to PH.For image description, please refer to the figure legend and surrounding text.

Read PDF

Similar papers

Open access Oct 2026

Phenotyping of pulmonary arterial hypertension associated with congenital heart disease using latent class analysis: insights from a national prospective registry

Using LCA, distinct phenogroups within PAH-CHD were identified with varying clinical profiles, long-term survival, and treatment responses, which may help to refine prognostic assessments and treatment strategies.

Q. Li, Q. Yu, G.-Z. Zhang et al. · 0 citations
Open access Oct 2026

Phenotypic characterization of pulmonary hypertension associated with left heart disease in contemporary practice: insights from the Re-PHIRE Trial

The Re-PHIRE trial provides one of the largest contemporary multi-country cohorts of patients with RHC-confirmed diagnosis of PH-LHD across the EF continuum and a wide PVR range, thereby capturing a spectrum of haemodynamic and clinical phenotypes.

E. Surkova, M. Ufnal, M. Ciurzyński et al. · 0 citations
Open access Sep 2026

Non-invasive risk stratification of pulmonary hypertension in idiopathic pulmonary fibrosis: a screening approach from a prospective observational study.

Pulmonary hypertension (PH) is a major complication of idiopathic pulmonary fibrosis (IPF), but its detection remains challenging because right-heart catheterization is invasive and echocardiography has limited accuracy in advanced lung disease. We assessed the feasibility of a multiparametric non-invasive screening ap...

S. Behbeh, A. Ketfi · 0 citations
Open access Oct 2026

Deep phenotyping of the right ventricular–pulmonary circulation reveals biological overlap between pulmonary arterial hypertension and combined post-capillary pulmonary hypertension

The distinction between pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with left heart disease (PH-LHD) remains clinically relevant but biologically uncertain, particularly in combined post- and precapillary PH (CpcPH) and PAH associated with cardiovascular comorbidities (coPAH)....

J. J. Rodríguez-Arias, C. Palacios, B. Ayala et al. · 0 citations
Open access Sep 2026

Pulmonary hypertension optimal screening in interstitial lung disease (PHOS-ILD): a scoring system for the detection of pulmonary hypertension in patients with interstitial lung disease

Background Pulmonary hypertension (PH) is a common comorbidity of interstitial lung disease (ILD). Timely detection may improve outcomes through implementation of PH specific treatments. Methods Retrospective, multicenter study aiming to identify features that predict PH in patients with ILD. In the derivation cohort (...

T. Karampitsakos, E. Wasserman, E. Stagaki et al. · 0 citations
Review Open access Oct 2026

Outcome and prognostic factors in patients with adult congenital heart disease and pulmonary vascular disease: insights from a nationwide cohort of 1,067 patients

Pulmonary vascular disease (PVD) and pulmonary hypertension (PH) are associated with considerable morbidity and mortality in adults with congenital heart disease (ACHD). In PVD especially patients in univentricular circulation represent a complex and expanding high-risk population. Contemporary real-world data de...

M. L. Benesch Vidal, C. Pfitzer, T. Pickardt et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.